BioWorld

Aug. 5, 2005

FDA Committee Wants More Data For MT 100 In Migraine

ROCKVILLE, Md. - Prospects are growing dim for MT 100, a migraine drug developed by Pozen Inc. (BioWorld Today) Read More

ZymoGenetics Gets $135M To Advance rhThrombin

Par Dropping Advancis Deal After Amoxicillin Pulsys Miss

Predix IPO Seeks $70M; Phase III Program Starts

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...